Hormonal
Bariatric surgery reduces the incidence of macro- and micro-vascular complications in obese patients with type 2 diabetes, but it does not reliably reverse established end-stage complications (such as advanced nephropathy or retinopathy) and may not improve survival in patients with advanced comorbidities.
If you have obesity and diabetes with existing vascular issues (like high blood pressure or early kidney changes), surgery can significantly lower your risk of heart attacks, strokes, and blindness. However, if you already have end-stage organ damage (like dialysis-dependent kidney failure), surgery is unlikely to reverse that damage and may carry higher risks. The goal of surgery is prevention of these events, not necessarily curing established end-stage disease.
Having had a bariatric procedure was associated with a lower risk of any vascular event (combined outcome), any macro-vascular event, any micro-vascular event or any other vascular event... On the contrary, the effects of bariatric surgery on established complications are far less good and patients with advanced or complicated disease may do not benefit in term of total mortality.
Why this rating
Supported by large retrospective and prospective studies (SOS, Johnson et al.), though not all are RCTs.
Source
Timing of bariatric surgery in people with obesity and diabetes.
Luca Busetto · PubMed · 2015
DOI 10.3978/j.issn.2305-5839.2015.03.62
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →